Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thermal Cures in the Treatment of Multiple Sclerosis (SPA-SEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03915028
Recruitment Status : Recruiting
First Posted : April 16, 2019
Last Update Posted : July 10, 2019
Sponsor:
Information provided by (Responsible Party):
Association Francaise pour la Recherche Thermale

Brief Summary:
Multiple Sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, with significant public health consequences. The benefit of spa treatments on the quality of life in this population has not been evaluated. The methods of study in clinical pharmacology can be a scientific methodological model for the evaluation of thermal practices and it is in this perspective that investigators want to lead this project.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Other: Spa therapy Not Applicable

Detailed Description:
Multiple sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, and its consequences in terms of public health are important. In this disease, the alteration of the quality of life (QoL) is constant and multifactorial : pain, fatigue, decrease in functional capacities, sleep disorders, cognitive disorders, vesico-sphincterian disorders, anomolytic disorders. -rectal and genito-sexual. The benefit of thermal cures on the quality of life in this population has not been evaluated, even if there is some literature in the literature suggesting a benefit of hydrotherapy on equilibrium or on pain.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Thermal Cures in the Treatment of Multiple Sclerosis: Effectiveness on the Quality of Life
Actual Study Start Date : May 23, 2019
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treated group by thermal cure
Treated group will benefit, within 6 weeks of the inclusion, from the thermal cure in one of the thermal establishments.
Other: Spa therapy

The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.

Each day, the patient receives at least four treatments, among which:

  • Cure of Drink (in addition to 4 daily cares)
  • Bath in running water: Bath
  • Bath in running water: Pool at 32 ° C
  • Bath with aerobain
  • Immersion shower bath
  • Shower of high pressure under immersion in swimming pool
  • General penetrating shower
  • General jet shower
  • Local jet shower
  • Local mud bath at the feet
  • Single poultice
  • Multiple poultice
  • Compress
  • Mobilization pool
  • Massages under water

No Intervention: Control group
Control group will receive a thermal cure after the end of the study



Primary Outcome Measures :
  1. Benefit of spa treatment on quality of life assessed by the scale SEP-59 [ Time Frame: within 15 weeks after inclusion ]
    Difference of the score of quality of live assessed by the scale SEP-59 between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. SEP-59 is built on the basis of a generic scale, the SF-36. The analysis of SEP-59 is done by computer processing in order to calculate the score of the various axes (pain, physical activity, general wellbeing ...) which are independent (there is no overall score).


Secondary Outcome Measures :
  1. Benefit of a spa treatment based on average number of steps per day for one week assessed by actimeter [ Time Frame: 9 weeks after inclusion ]
    Difference of the average number of steps per day for one week between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately.

  2. Benefit of a thermal cure based on treatment consumption of hospital and ambulatory care [ Time Frame: 15 to 17 weeks after inclusion ]
    Difference of the number of treatment consumption of hospital and ambulatory care between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately

  3. Benefit of a thermal cure based on depression and anxiety assessed by the scale Hospital Anxiety and depression scale [ Time Frame: 15 to 17 weeks after inclusion ]

    Difference of the level of pain assessed by the scale Hospital Anxiety and depression between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately.HADS is a self-administered scale of 14 items, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). It contains no somatic item that can be confused with symptomatic manifestations of a disease.

    Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales and for the entire HADS (HADS-T).

    Limit scores distinguish between: non-cases or asymptomatic cases (score ≤ 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score ≥ 11).


  4. Benefit of a thermal cure based on tiredness assesed by the fatigue impact scale [ Time Frame: 15 to 17 weeks after inclusion ]
    Difference of the level of pain assessed by the fatigue impact scale between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. It is a self-assessment tool in which the patient is asked to note the extent to which fatigue has caused them problems in certain situations. (0 = no problem, 4 = extreme problems). A maximum score of 160 is obtained for the 40 items.

  5. Benefit of a thermal cure regarding pain assessed by the scale DN 4 [ Time Frame: 15 to 17 weeks after inclusion ]
    Difference of the level of pain assessed by the DN4 scale between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient with primary or progressive secondary-phase MS
  • Showing EDSS <7 severity criteria
  • Patient with MS for whom an indication of spa treatment has been made,
  • Patient agreeing to participate in this study and therefore accepting the constraints related to the design "immediate cure-deferred cure",
  • Patient receiving the general social security scheme,
  • Patient having given written consent to participate in the study

Exclusion Criteria:

  • Patient does not meet the inclusion criteria,
  • Patient with relapsing remitting MS
  • Patient unfit according to the investigator to complete the rating scales
  • Patient with heat intolerance called "Uhthoff effect"
  • Patient with a contraindication to the spa treatment: urinary or faecal leakage, wound, thrombophlebitis less than three months old, unstabilized cardio respiratory disease.
  • Patient with serious life-threatening condition (ie, cancer)
  • Patient under tutorship or curatorship
  • Patient participating in another interventional clinical research project

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03915028


Contacts
Layout table for location contacts
Contact: Isabelle LAFFONT 04 67 33 23 46 i-laffont@chu-montpellier.fr

Locations
Layout table for location information
France
Département de Médecine Physique et de Réadaptation, Hopital LAPEYRONIE Recruiting
Montpellier, France, 34295
Contact: Isabelle LAFFONT, PU-PH    0467338664    i-laffont@chu-montpellier.fr   
Sponsors and Collaborators
Association Francaise pour la Recherche Thermale
Layout table for additonal information
Responsible Party: Association Francaise pour la Recherche Thermale
ClinicalTrials.gov Identifier: NCT03915028    
Other Study ID Numbers: 2018-A02411-54
First Posted: April 16, 2019    Key Record Dates
Last Update Posted: July 10, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Association Francaise pour la Recherche Thermale:
Multiple sclerosis
Spa treatment
Crenotherapy
Balneotherapy
Physical exercise
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases